# electroCore to Participate at the 38th Annual Roth Conference
Canonical URL: https://biopharmsignal.com/news/ECOR/electrocore-to-participate-at-the-38th-annual-roth-conference-da42a9a3
Ticker: ECOR
Company: electroCore
Source: electroCore
Published: 2026-03-10 12:00 EST
## Summary

electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that...

## Article Body
electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California. Joshua Lev, Chief Financial Officer, will host one-on-one meetings at the conference.

Investors attending this event who are interested in scheduling a meeting with management can do so by contacting their respective Roth representative, or by emailing investors@electrocore.com for more information.

About the Roth Capital Partners Conference The Annual ROTH Conference is one of the largest in the nation for small-cap companies, combining company presentations, Q&A sessions and management 1-on-1 meetings. The format provides investors with the opportunity to hear from and meet with executive management from approximately 500 private and public companies in a variety of growth sectors. Roth’s award-winning Research Team identifies distinguished presenting companies across broad sectors, including consumer, energy, healthcare, industrial growth, metals & mining, sustainability, services, technology and more.

About electroCore, Inc. electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell ® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Trvuaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com .

Contact

ECOR Investor Relations (973) 302-9253 investors@electrocore.com
## Recent Company News
- 2026-07-16 12:00 EST — [New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation](https://biopharmsignal.com/news/ECOR/new-review-examines-anatomical-and-methodological-differences-between-auricular--75858401) — Source: electroCore
- 2026-06-17 12:00 EST — [electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference](https://biopharmsignal.com/news/ECOR/electrocore-to-participate-in-iaccess-alpha-virtual-best-ideas-summer-investment-07437969) — Source: electroCore
- 2026-06-09 12:00 EST — [Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery](https://biopharmsignal.com/news/ECOR/frontiers-in-neuroscience-accepts-review-article-synthesizing-evidence-that-cerv-90a5568d) — Source: electroCore
- 2026-06-02 12:00 EST — [electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub](https://biopharmsignal.com/news/ECOR/electrocore-to-present-at-the-planet-microcap-las-vegas-2026-powered-by-microcap-9774a6c0) — Source: electroCore
- 2026-05-13 12:00 EST — [electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia](https://biopharmsignal.com/news/ECOR/electrocore-announces-publication-in-jama-highlighting-the-benefits-of-adding-qu-c4813dca) — Source: electroCore
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)